Inhibition of AMPK signalling by doxorubicin: at the crossroads of the cardiac responses to energetic, oxidative, and genotoxic stress
Open Access
- 28 March 2012
- journal article
- research article
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 95 (3), 290-299
- https://doi.org/10.1093/cvr/cvs134
Abstract
Cardiotoxic side effects of anthracyclines, the most widely used anticancer drugs, are well documented, while mechanisms involved are not fully elucidated. The cellular energy sensor and regulator AMP-activated protein kinase (AMPK) was suggested as a putative mediator of cardiotoxicity of doxorubicin, the leading anthracycline drug, by our earlier work. Here, we study the interference of doxorubicin with AMPK signalling and potentially involved mechanisms. Effects of doxorubicin on cell signalling are studied in isolated Langendorff-perfused Wistar rat hearts and in hearts from doxorubicin-treated Wistar rats. In both models, doxorubicin induces energetic, oxidative, and genotoxic stress. Despite energy depletion and unaffected AMPK upstream signalling, doxorubicin does not activate the AMPK pathway and even reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. In contrast, oxidative and genotoxic stress do activate pro-survival mitogen-activated protein kinase (MAPK) and Akt pathways, the latter via DNA-dependent protein kinase activation triggered by DNA damage. Combined inhibition of AMPK and activation of Akt and MAPK lead to activation of growth-stimulating mammalian target of rapamycin (mTOR) signalling. Our results suggest that in the doxorubicin-challenged heart, a combined energetic, oxidative, and genotoxic stress elicits a specific, hierarchical response where AMPK is inhibited at least partially by the known negative cross-talk with Akt and MAPK pathways, largely triggered by DNA damage signalling. Although such signalling can be protective, e.g. by limiting apoptosis, it primarily induces a negative feedback that increases cellular energy deficits, and via activation of mTOR signalling, it also contributes to the pathological cardiac phenotype in chronic doxorubicin toxicity.Keywords
This publication has 54 references indexed in Scilit:
- AMP-activated protein kinase—an energy sensor that regulates all aspects of cell functionGenes & Development, 2011
- Regulation of the mTOR Complex 1 Pathway by Nutrients, Growth Factors, and StressMolecular Cell, 2010
- Protection from Doxorubicin-Induced Cardiomyopathy Using the Modified Anthracycline N-Benzyladriamycin-14-valerate (AD 198)The Journal of pharmacology and experimental therapeutics, 2010
- S6K1 is a multifaceted regulator of Mdm2 that connects nutrient status and DNA damage responseThe EMBO Journal, 2010
- Transcription Factor GATA4 Inhibits Doxorubicin-induced Autophagy and Cardiomyocyte DeathOnline Journal of Public Health Informatics, 2010
- Cardiac-specific Deletion of LKB1 Leads to Hypertrophy and DysfunctionOnline Journal of Public Health Informatics, 2009
- LKB1 and AMP‐activated protein kinase control of mTOR signalling and growthActa Physiologica, 2009
- A complex interplay between Akt, TSC2 and the two mTOR complexesBiochemical Society Transactions, 2009
- Molecular system bioenergetics: regulation of substrate supply in response to heart energy demandsJournal Of Physiology-London, 2006
- AMPK alterations in cardiac physiology and pathology: enemy or ally?Journal Of Physiology-London, 2006